Radiopharmaceuticals Market By Type, Procedural Volumes and Application- Global Industry Analysis and Forecast to 2023
Radiopharmaceuticals Market from Qurate’s Repository provides detailed information, in-depth analysis, and forecast which is developed by a team of experts and professionals
(EMAILWIRE.COM, August 22, 2018 ) Industry Outlook and Trend Analysis
The global Radiopharmaceuticals market was worth USD 3.89 billion in 2014 and is expected to reach approximately USD 8.77 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 9.45% during the forecast period. The market is right now in its development phase driven by expanding number of disease cases and increasing awareness about nuclear medication. Radiopharmaceuticals are pharmaceutical formulations involving radioactive isotopes that are useful as a part of analysis and therapeutics. They are basic and small substances that contain a radioactive substance that is useful as a part of the treatment of cancer and neurological and cardiac disorders. The regular chemotherapy techniques are being supplanted by more advantageous helpful radiopharmaceuticals for oncology and cancer treatment, which opens up new roads in the radiopharmaceuticals market.
Request Sample Report@ https://www.qurateresearch.com/report/sample/CnM/QBI-CMR-CnM-54683
Type Outlook and Trend Analysis
On the basis of type, the market is fragmented into therapeutic and diagnostic. The diagnostic portion represented the biggest share of the nuclear medicine market. The diagnostic portion is additionally fragmented into PET and SPECT. In 2016, the SPECT section represented the biggest share of the radiopharmaceuticals diagnostic market. The therapeutic fragment is additionally divided into brachytherapy, alpha emitters, and beta emitters. In 2016, the beta producers section represented the biggest share of the atomic prescription/radiopharmaceuticals therapeutic market.
Application Outlook and Trend Analysis
Based on application, the radiopharmaceuticals market is fragmented into PET, SPECT and therapeutic applications. In 2016, the cardiology application section represented the biggest share of the atomic medication SPECT applications market. The atomic radiopharmaceuticals PET applications market was ruled by the oncology section, while the radiopharmaceuticals therapeutic applications market was ruled by the thyroid application fragment.
Regional Outlook and Trend Analysis
Geographically, the market is fragmented into Europe, North America, Asia-Pacific, and the Rest of the World. North America is accounted for the biggest share, trailed by Asia-Pacific and Europe In 2016. The Asia-Pacific locale is foreseen to develop at the most elevated CAGR amid the estimate time frame. This high development can be ascribed to the establishment of PET scanners in India and activities by the legislature of the Asian nations to advance health among others.
Competitive Insights
The leading players in the market are Bracco Imaging S.p.A, IBA Molecular Imaging India Private Limited, Wipro GE Healthcare Pvt Ltd, Bayer HealthCare Pharmaceuticals LLC, Nordion Inc, Lantheus Medical Imaging Inc, Cardinal Health, Advanced Accelerator Applications and Mallinckrodt.
Enquiry Before Buy@ https://www.qurateresearch.com/report/enquiry/CnM/QBI-CMR-CnM-54683
By Type
Diagnostic Nuclear Medicine/Radiopharmaceuticals
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine/Radiopharmaceuticals
Beta Emitters
Alpha Emitters
Brachytherapy
By Procedural Volumes
Diagnostic Procedures
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Procedures
Beta Emitters
Alpha Emitters
Brachytherapy
By Application
Diagnostic Applications
SPECT
PET
Therapeutic Applications
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Russia
Italy
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific
South America
Brazil
Argentina
Columbia
South Africa
Rest of South America
Middle East and Africa
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Enquiry for Discount@ https://www.qurateresearch.com/report/discount/CnM/QBI-CMR-CnM-54683
The global Radiopharmaceuticals market was worth USD 3.89 billion in 2014 and is expected to reach approximately USD 8.77 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 9.45% during the forecast period. The market is right now in its development phase driven by expanding number of disease cases and increasing awareness about nuclear medication. Radiopharmaceuticals are pharmaceutical formulations involving radioactive isotopes that are useful as a part of analysis and therapeutics. They are basic and small substances that contain a radioactive substance that is useful as a part of the treatment of cancer and neurological and cardiac disorders. The regular chemotherapy techniques are being supplanted by more advantageous helpful radiopharmaceuticals for oncology and cancer treatment, which opens up new roads in the radiopharmaceuticals market.
Request Sample Report@ https://www.qurateresearch.com/report/sample/CnM/QBI-CMR-CnM-54683
Type Outlook and Trend Analysis
On the basis of type, the market is fragmented into therapeutic and diagnostic. The diagnostic portion represented the biggest share of the nuclear medicine market. The diagnostic portion is additionally fragmented into PET and SPECT. In 2016, the SPECT section represented the biggest share of the radiopharmaceuticals diagnostic market. The therapeutic fragment is additionally divided into brachytherapy, alpha emitters, and beta emitters. In 2016, the beta producers section represented the biggest share of the atomic prescription/radiopharmaceuticals therapeutic market.
Application Outlook and Trend Analysis
Based on application, the radiopharmaceuticals market is fragmented into PET, SPECT and therapeutic applications. In 2016, the cardiology application section represented the biggest share of the atomic medication SPECT applications market. The atomic radiopharmaceuticals PET applications market was ruled by the oncology section, while the radiopharmaceuticals therapeutic applications market was ruled by the thyroid application fragment.
Regional Outlook and Trend Analysis
Geographically, the market is fragmented into Europe, North America, Asia-Pacific, and the Rest of the World. North America is accounted for the biggest share, trailed by Asia-Pacific and Europe In 2016. The Asia-Pacific locale is foreseen to develop at the most elevated CAGR amid the estimate time frame. This high development can be ascribed to the establishment of PET scanners in India and activities by the legislature of the Asian nations to advance health among others.
Competitive Insights
The leading players in the market are Bracco Imaging S.p.A, IBA Molecular Imaging India Private Limited, Wipro GE Healthcare Pvt Ltd, Bayer HealthCare Pharmaceuticals LLC, Nordion Inc, Lantheus Medical Imaging Inc, Cardinal Health, Advanced Accelerator Applications and Mallinckrodt.
Enquiry Before Buy@ https://www.qurateresearch.com/report/enquiry/CnM/QBI-CMR-CnM-54683
By Type
Diagnostic Nuclear Medicine/Radiopharmaceuticals
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine/Radiopharmaceuticals
Beta Emitters
Alpha Emitters
Brachytherapy
By Procedural Volumes
Diagnostic Procedures
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Procedures
Beta Emitters
Alpha Emitters
Brachytherapy
By Application
Diagnostic Applications
SPECT
PET
Therapeutic Applications
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Russia
Italy
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific
South America
Brazil
Argentina
Columbia
South Africa
Rest of South America
Middle East and Africa
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Enquiry for Discount@ https://www.qurateresearch.com/report/discount/CnM/QBI-CMR-CnM-54683
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results